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1025-41 Insulin Sensitizers Are Associated With Improved 
Outcomes in Diabetic Patients Undergoing 
Brachytherapy
John A. Kao, Mark Grise, Peter Castarella, Huan Giap, Aniradha Koka, Gerard Huppe, 
Kathleen Sirkin, Prabhakar Tripuraneni, Paul S. Teirstein, Scripps Clinic, La Jolla, CA
BACKGROUND: Diabetics have worse baseline disease and higher restenosis rates
than non-diabetics. Insulin sensitizers may decrease cardiovascular events in diabetics.
Our goal was to determine the effect of insulin sensitizers on clinical events of diabetics
undergoing brachytherapy for in-stent restenosis.
METHODS: Diabetics receiving brachytherapy in SCRIPPS I, II, III, and IV at Scripps
Clinic were divided into two groups; insulin sensitizers (biguanides or thiazolidinediones,
n=50), and non-sensitizers (insulin, sulfonylureas or diet, n=67). Clinical events were
defined as target vessel revascularization (TVR), MI (STEMI and NSTEMI), non-TVR,
and death.
RESULTS: By 12 months a significant reduction in the composite endpoint was observed
in the insulin sensitizer group with a significant decrease in the individual endpoint of
Death. Treatment with an insulin sensitizer was the strongest predictor of clinical events
(OR=3.47, p=0.0035). This effect was independent of adjunctive medical therapy for cor-
onary artery disease. Patients treated with insulin alone had equivalent outcomes com-
pared to patients treated with sulfonylureas or sulfonylureas with insulin (p>0.05 for all
comparisons).
CONCLUSIONS: Insulin sensitizers improve clinical outcomes and convey a mortality
benefit in diabetics undergoing brachytherapy for in-stent restenosis. The increased
events in the non-sensitizer group is not driven by by patients receiving insulin therapy. 
1025-42 Abciximab Administration for the Prevention of 
Angiographic Restenosis in Small Coronary Arteries: 
Results From the Randomized ISAR-SMART-2 Trial
Jörg Hausleiter, Adnan Kastrati, Julinda Mehilli, Helmut Schühlen, Sonja Siebert, Franz 
Dotzer, Josef Dirschinger, Albert Schömig, Deutsches Herzzentrum München, Munich, 
Germany, 1.Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
On the basis of non-dedicated studies it is believed that abciximab reduces the risk of
restenosis after percutaneous coronary interventions. In the current multi-center trial,
patients with symptomatic coronary artery disease and lesions in small coronary arteries
(vessel size < 2.8mm) were randomized to receive stenting (phosphorylcholine-coated
stent) or PTCA as well as abciximab or placebo by a 2x2 factorial design. The objective
of the pharmacological aspect of the ISAR-SMART-2 trial was to assess whether abcix-
imab administration is associated with a reduction in angiographic restenosis in small
coronary arteries.
Methods: From July 2000 through May 2002, a total of 502 patients were randomly
assigned to abciximab administration (251 pts) or placebo (251 pts). The primary end-
point of the study was the incidence of angiographic restenosis (>= 50% diameter steno-
sis) at repeat angiography (available in 82% of patients). All patients received a loading
dose of 600mg clopidogrel at least 2 hours before the intervention.
Results: The incidence of major adverse cardiac events did not differ at 30 days after
intervention. The restenosis rate and the rate of target vessel revascularization at 1 year
are shown in the Figure.
Conclusion: These results show that abciximab administration on top of an high-dose clo-
pidogrel loading does not provide protection against restenosis after percutaneous coro-
nary interventions in small coronary arteries. 
1025-43 Bivalirudin Confers Antiplatelet Effects in Patients 
Undergoing Percutaneous Coronary Intervention
Sunil X. Anand, Michael C. Kim, Mazullah Kamran, Samin K. Sharma, Frank Carbon, 
Erdal Cavusoglu, Juan F. Viles-Gonzalez, Juan J. Badimon, Jonathan D. Marmur, The 
Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai School of Medicine, 
New York, NY, SUNY Health Science Center at Brooklyn, Brooklyn, NY
Background: Thrombin activity is paramount in the formation of platelet-mediated acute
thrombosis precipitated by atherosclerotic plaque rupture or endothelium disruption
resulting from mechanical intervention. The objective of this study was to investigate and
compare the effects of a bivalent direct thrombin inhibitor, bivalirudin, with unfractionated
heparin (UFH) on platelet function in the setting of percutaneous coronary intervention
(PCI).
Methods: Patients (mean age 61.7 ± 11.1) were administered an intravenous 0.75 mg/
kg bolus followed by a 1.75 mg/kg/hr infusion of bivalirudin (n=12) or an intravenous 40-
50 U/kg bolus of UFH (n=15) during PCI. No patient received a pre-loading dose of clopi-
dogrel. Blood samples were collected from patients at baseline and 5 minutes after drug
administration from the femoral artery access sheath. To determine platelet function (by
assessing platelet surface coverage), the cone and platelet analyzer assay was per-
formed on all samples at a high shear rate (1875 s-1). Computerized planimetry mea-
surements were performed, and 4 to 16 images per timepoint were quantified for platelet
surface coverage (PSC) in a blinded fashion.
Results: Direct thrombin inhibition by bivalirudin resulted in a marked 34 ± 6 % reduction
in PSC as compared to baseline values (*p < 0.001). On the other hand, UFH demon-
strated a remarkable 29 ± 8% increase in PSC as compared to baseline values (*p <
0.05). No clinical sequalae were experienced by any patient.
Conclusion: Our data suggests that direct thrombin inhibition by bivalirudin administra-
tion during PCI confers a profound anti-platelet effect as compared to UFH. Interestingly,
UFH administration leads to significant platelet activation and aggregation during PCI.
Sensitizers
N=50
Non-Sensitizer 
Therapy
N=67
P Value
6-Month Combined Event Rate (%) 27.3% 31.9% 0.72
Death 0 7% 0.13
MI 6% 9% 0.81
TVR 18% 18% 0.33
Non-TVR 15% 10% 0.33
12 Month Combined Event Rate (%) 37% 57.4% 0.041
Death 0 10% 0.049
MI 6% 12% 0.44
TVR 30% 30% 0.61
Non-TVR 10% 15% 0.61
